Status:
COMPLETED
Vitamin D and Grass Pollen Specific Immunotherapy
Lead Sponsor:
Charite University, Berlin, Germany
Conditions:
Allergic Rhinoconjunctivitis
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
Allergen-specific immunotherapy is the only causal therapy of Immunoglobulin E-induced allergies like allergic rhinoconjunctivitis. Despite progress during the last decades it is limited by a long tre...
Eligibility Criteria
Inclusion
- written informed consent
- relative Vitamin D deficiency
- clinical relevant grass pollen allergy
- positive intradermal test with grass pollen
- forced expiratory volume at one second (FEV1) \> 70%
Exclusion
- current specific immunotherapy
- instable allergic asthma
- pregnancy and lactation
- treatment with immunomodulators or immunosuppressive drugs
- sarcoidosis, chronic diseases, malignancy
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01466465
Start Date
October 1 2011
End Date
January 1 2015
Last Update
June 25 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité Universitätsmedizin Berlin, Allergy-Centre-Charité, CCM
Berlin, Germany, 10117